Elvucitabine

This article needs to be updated. Please help update this article to reflect recent events or newly available information. (January 2014)

Elvucitabine

Clinical data
ATC code	none
Identifiers
IUPAC name 4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
JSmol)	Interactive image
SMILES c1c(c(nc(=O)n1[C@@H]2C=C[C@@H](O2)CO)N)F
InChI InChI=1S/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m1/s1 Key:HSBKFSPNDWWPSL-VDTYLAMSSA-N
NY (what is this?)  (verify)

Elvucitabine is an experimental

Elvucitabine belongs to a class of HIV drugs called nucleoside reverse transcriptase inhibitors (NRTIs).[2] By blocking reverse transcriptase enzymes, NRTIs prevent HIV from multiplying and can reduce the amount of HIV in the body.

Elvucitabine is similar in chemical structure to the FDA-approved NRTIs lamivudine (brand name Epivir) and emtricitabine (brand name Emtriva). However, in vitro studies have suggested that elvucitabine may affect certain HIV strains resistant to other NRTIs, such as lamivudine and emtricitabine.

Studies have also suggested that elvucitabine may be effective against hepatitis B virus (HBV).^[3] Mechanism of action of Elvucitabine ; reveals that it acts by inhibiting reverse transcriptase which interferes with generation of DNA copies of viral RNA.^[4]

Currently, it is in Phase II clinical trials.^[5]

References